Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
PaperCitations, authors & open-access status
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 47 citations, 2022 year and closed oa status.
47
Citations
2022
Year
closed
OA Status